SOLENO THERAPEUTICS INC (SLNO) — SEC Filings

Latest SEC filings for SOLENO THERAPEUTICS INC (SLNO), explained in plain English.

Sentiment Overview: 2 bullish, 47 neutral, 1 mixed

Recent Filings (50)

• Soleno Therapeutics Files Schedule 14D-9 for Merger — SC14D9C · 2026-04-06T17:17:37-04:00 [neutral] Risk: low
  Soleno Therapeutics, Inc. has filed a Schedule 14D-9 in relation to an Agreement and Plan of Merger dated April 5, 2026, with Neurocrine Biosciences, Inc. and S
• Soleno Therapeutics Files Material Definitive Agreement — 8-K · 2026-04-06T07:46:57-04:00 [neutral] Risk: medium
  On April 6, 2026, Soleno Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as the agreement its
• Soleno Therapeutics Enters Material Agreement, Creates Financial Obligation — 8-K · 2025-11-12T00:00:00.000Z [neutral] Risk: medium
  On November 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction.
• SLNO Swings to Profit on VYKAT XR Launch, Cash Reserves Soar — 10-Q · 2025-11-04T00:00:00.000Z [bullish] Risk: medium
  Soleno Therapeutics Inc. (SLNO) reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $26.013 mil
• Solen Therapeutics Reports Director Changes and Compensation Adjustments — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensa
• Soleno Therapeutics Files 8-K — 8-K · 2025-09-10T00:00:00.000Z [neutral] Risk: low
  On September 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information
• Soleno Therapeutics Files 8-K — 8-K · 2025-08-18T00:00:00.000Z [neutral] Risk: low
  On August 18, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Soleno Therapeutics Files 8-K — 8-K · 2025-08-06T00:00:00.000Z [neutral] Risk: low
  On August 6, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st. Soleno Therapeutics, for
• Solenos Net Loss Widens 18% Amid R&D Surge; $100M Offering Boosts Cash — 10-Q · 2025-08-06T00:00:00.000Z [mixed] Risk: high
  SOLENO THERAPEUTICS INC reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company incurred a net loss o
• Soleno Therapeutics Enters Material Definitive Agreement — 8-K · 2025-07-11T00:00:00.000Z [neutral] Risk: medium
  On July 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• Soleno Therapeutics Files 8-K on Operations — 8-K · 2025-07-10T00:00:00.000Z [neutral] Risk: low
  On July 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Soleno Therapeutics Files 8-K on Security Holder Vote Matters — 8-K · 2025-06-06T00:00:00.000Z [neutral] Risk: low
  On June 5, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify
• Soleno Therapeutics Files 8-K on Operations and Financials — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  On May 7, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• Solen Therapeutics Files Q1 2025 10-Q — 10-Q · 2025-05-07T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Capnia, Inc., is involved in electromedical and elec
• Solen Therapeutics Files Annual Proxy Statement — DEF 14A · 2025-04-22T00:00:00.000Z [neutral] Risk: low
  Solen Therapeutics Inc. filed its DEF 14A on April 22, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other c
• Soleno Therapeutics Changes Independent Auditor — 8-K · 2025-04-18T00:00:00.000Z [neutral] Risk: low
  On April 17, 2025, Soleno Therapeutics, Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed PricewaterhouseCoo
• Soleno Therapeutics Files 8-K on Financials — 8-K · 2025-03-26T00:00:00.000Z [neutral] Risk: low
  On March 26, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The company, formerly known as Cap
• Solen Therapeutics Files 2024 10-K — 10-K · 2025-02-28T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Capnia,
• Soleno Therapeutics Files 8-K on Financials — 8-K · 2025-02-27T00:00:00.000Z [neutral] Risk: low
  On February 27, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Soleno Therapeutics Announces Board and Executive Changes — 8-K · 2025-01-24T00:00:00.000Z [neutral] Risk: medium
  On January 21, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
• Soleno Therapeutics Enters Material Definitive Agreement — 8-K · 2024-12-17T00:00:00.000Z [neutral] Risk: medium
  On December 17, 2024, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company, formerly
• Soleno Therapeutics Files 8-K — 8-K · 2024-11-26T00:00:00.000Z [neutral] Risk: low
  On November 26, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine updat
• Perceptive Advisors Amends Soleno Therapeutics Stake — SC 13D/A · 2024-11-19T00:00:00.000Z [neutral] Risk: medium
  On November 19, 2024, Perceptive Advisors LLC, through its fund Perceptive Life Sciences Master Fund, Ltd., filed an amendment (No. 8) to its Schedule 13D regar
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Perceptive Advisors Adjusts Soleno Therapeutics Stake — SC 13D/A · 2024-11-14T00:00:00.000Z [neutral] Risk: medium
  Perceptive Advisors LLC, through its affiliated entities, has amended its Schedule 13D filing regarding Soleno Therapeutics, Inc. as of November 14, 2024. The f
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• Soleno Therapeutics Files 8-K on Financials — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  On November 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Solen Therapeutics Files Q3 2024 10-Q — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Capnia, Inc., is incorporated in Delaware and he
• SC 13G Filing — SC 13G · 2024-10-24T00:00:00.000Z [neutral]
• Carlyle Group Adjusts Stake in Soleno Therapeutics — SC 13D/A · 2024-10-21T00:00:00.000Z [neutral] Risk: medium
  Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, have filed an amendment to their Schedule 13D, indicating a change in their bene
• Carlyle Group Files SC 13D/A Amendment for Soleno Therapeutics — SC 13D/A · 2024-10-15T00:00:00.000Z [neutral] Risk: medium
  On October 15, 2024, Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, filed an SC 13D/A amendment regarding their holdings in Sol
• Carlyle Group Adjusts Soleno Therapeutics Stake — SC 13D/A · 2024-10-10T00:00:00.000Z [neutral] Risk: medium
  On October 10, 2024, Carlyle Group Inc. and its affiliates filed an SC 13D/A amendment regarding their holdings in Soleno Therapeutics Inc. The filing indicates
• SC 13G Filing — SC 13G · 2024-10-03T00:00:00.000Z [neutral]
• Carlyle Group Files 13D Amendment for Soleno Therapeutics — SC 13D/A · 2024-09-10T00:00:00.000Z [neutral] Risk: medium
  Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, have filed an amendment to their Schedule 13D, reporting a change in beneficial
• SC 13G Filing — SC 13G · 2024-09-05T00:00:00.000Z [neutral]
• Soleno Therapeutics Appoints New Chief Medical Officer — 8-K · 2024-08-15T00:00:00.000Z [neutral] Risk: medium
  On August 9, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. G. Farquharson as Chief Medical Officer. Dr. Farquharson brings extens
• Soleno Therapeutics Files 8-K on Operations — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  On August 7, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, alo
• Solen Therapeutics Inc. Files Q2 2024 10-Q Report — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial data
• Solen Therapeutics Adds Directors, Adjusts Executive Pay — 8-K · 2024-07-19T00:00:00.000Z [neutral] Risk: medium
  Solen Therapeutics, Inc. announced on July 17, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company elect
• Soleno Therapeutics Closes $100M Public Offering — 8-K · 2024-06-28T00:00:00.000Z [bullish] Risk: medium
  On June 28, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing the closing of its previously announced underwritten public offering. The company succ
• Soleno Therapeutics Secures $50M Credit Facility — 8-K · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  On June 13, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to the Second Amended and Restated Cre
• Soleno Therapeutics Files 8-K on Security Holder Vote Matters — 8-K · 2024-06-06T00:00:00.000Z [neutral] Risk: low
  On June 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as C
• Soleno Therapeutics Files 8-K on Financials — 8-K · 2024-05-10T00:00:00.000Z [neutral] Risk: low
  On May 9, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is in
• Soleno Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  SOLENO THERAPEUTICS INC (SLNO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Soleno Therapeutics Inc. filed a 10-Q report for the period ending M
• Soleno Therapeutics Files 8-K: Material Agreement & Other Events — 8-K · 2024-05-07T00:00:00.000Z [neutral] Risk: medium
  On May 2, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed within the filing. The company also
• Vivo Opportunity Fund Ups Soleno Stake to 10.8% — SC 13D/A · 2024-05-01T00:00:00.000Z [neutral] Risk: medium
  Vivo Opportunity Fund Holdings, L.P. filed an amendment (No. 2) to its Schedule 13D on May 1, 2024, regarding its holdings in Soleno Therapeutics, Inc. The fili
• Soleno Therapeutics Merges with Altacell, Renamed ATCL — 8-K · 2024-04-29T00:00:00.000Z [neutral] Risk: medium
  On April 29, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing the completion of its merger with Altacell, Inc. The merger was approved by Soleno's
• Soleno Therapeutics Appoints New CMO and CSO, CMO Departs — 8-K · 2024-04-22T00:00:00.000Z [neutral] Risk: medium
  On April 17, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. Geller as Chief Medical Officer and Dr. David M. D. Smith as Chief Sci
• Soleno Therapeutics Files 8-K on Financials — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: low
  On March 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is